Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pyrotinib - Jiangsu Hengrui Medicine

Drug Profile

Pyrotinib - Jiangsu Hengrui Medicine

Alternative Names: BLTN; Irene; Pyrotinib maleate; Pyrroltinib maleate; SHR 1258

Latest Information Update: 22 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Hengrui Pharmaceutical
  • Developer Chinese Academy of Medical Sciences; Fudan University; Jiangsu Hengrui Medicine Co.; Peking Union Medical College Hospital; Shanghai Changzheng Hospital; Sun Yat-Sen University; Tongji University
  • Class Antineoplastics; Pyridines; Pyrrolidines; Quinolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HER2 positive breast cancer
  • Phase III Non-small cell lung cancer
  • No development reported Colorectal cancer; Gastric cancer; Urogenital cancer

Most Recent Events

  • 05 Dec 2023 Efficacy and adverse events data from the phase-II clinical trial in HER2-positive-breast-cancer presented at 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
  • 20 Oct 2023 Efficacy data from a phase II PICTURE trial in HER2 positive breast cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 28 Sep 2023 No recent reports of development identified for phase-0 development in Urogenital-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top